An NSCLC patient who developed CIP after atezolizumab treatment was reported to have elevated levels of C-reactive protein and interleukin-6 (IL-6), when compared with baseline levels34. The gene discussed is IL6; the disease is hereditary sensory and autonomic neuropathy.